Phase 4 Osteoarthritis Trial, Recruiting NCT07089251 Sponsor: King Abdullah International Medical Research Center Condition: Osteoarthritis
Back to Osteoarthritis

Phase 4 Osteoarthritis Trial, Recruiting

NCT07089251
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are having knee joint replacement surgery.
  • People of any nationality, whether Saudi or non-Saudi.
  • People who have a complete medical record available.

Who may not be able to join:

  • People who have end-stage kidney failure.
  • People who have severe scarring of the liver (cirrhosis).
  • People who have a condition that affects their blood's ability to clot properly.
  • People whose pre-surgery haemoglobin (a measure of red blood cells) is below 10 (confirm with trial site).
  • People who have had a stroke or heart attack in the past 12 months.
  • People who have a history of heart failure.
  • People who have a history of irregular heart rhythms (arrhythmia).
  • People who have a history of a tumour affecting adrenaline production (pheochromocytoma), an overactive thyroid (thyrotoxicosis), or increased pressure in the eye (glaucoma).
  • People who are pregnant or breastfeeding.
  • People who have a history of blood clots in the veins (deep venous thrombosis) or blood clots in the lungs (pulmonary embolism).
  • People who have a known allergy to epinephrine (adrenaline) or tranexamic acid.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Wazzan Aljuhani, MD, FRCSC, MBA, MMEd, King Abdulaziz Medical City, MNGHA

Phone: +966 55 994 4782

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
King Abdullah International Medical Research Center
Registry
ClinicalTrials.gov
Start date
15 July 2025
Est. completion
24 June 2027

Where this trial is recruiting

🇸🇦 Saudi Arabia

Primary endpoints

Perioperative blood loss

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov